Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

The FDA today approved Cervarix, a new vaccine to prevent cervical cancer and precancerous lesions caused by human papillomavirus (HPV) types 16 and 18. The vaccine is approved for use in girls and women ages 10 years through 25 years.

19 Oct 2009

Chinese SFDA approves China Medical Technologies' SPR System

China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its SPR- based analysis system (the "SPR System") from the State Food and Drug Administration of China (the "SFDA").

19 Oct 2009

Majority of girls and young women well aware of HPV vaccine's benefits and limitations

Contrary to concerns that the human papillomavirus vaccine might promote promiscuity, a national survey of girls and young women found that the majority of respondents did not believe the HPV vaccine protected them against other sexually transmitted infections.

19 Oct 2009

Phase I clinical study of PENNVAX-B preventive DNA vaccine using electroporation technology

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, and the HIV Vaccine Trials Network (HVTN) announced today the initiation of a phase I clinical study of Inovio’s PENNVAX-B preventive DNA vaccine delivered using its proprietary electroporation technology.

19 Oct 2009

FDA approves Gardasil vaccine usage in boys and men for preventing genital warts

The U.S. Food and Drug Administration today approved use of the vaccine Gardasil for the prevention of genital warts (condyloma acuminata) due to human papillomavirus (HPV) types 6 and 11 in boys and men, ages 9 through 26.

19 Oct 2009

GlaxoSmithKline receives FDA approval for cervical cancer vaccine

GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10-25).

19 Oct 2009

Vaccination against HPV will help decrease cervical cancer death rate in India

Although a wide spectrum of human papillomavirus is seen across the population of India, HPV-16 and HPV-18 are the most common types and a vaccination targeting these types could eliminate 75 percent of the cervical cancers in the region, according to data presented at the American Association for Cancer Research Frontiers in Basic Cancer Research Meeting.

12 Oct 2009

Research study on HPV vaccination efficacy for boys and girls

Persistent infection with high-risk types of human papillomavirus (HPV), a sexually transmitted virus, is known to be a cause of cervical cancer. Current guidelines prioritize HPV vaccination of pre-adolescent girls, which has been shown to be cost-effective in previous studies, but the value of vaccinating boys in the United States has been unclear.

9 Oct 2009

New study finds rare type of head and neck cancer caused by HPV

An increase in cases of a rare type of head and neck cancer appears to be linked to HPV, or human papillomavirus, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

8 Oct 2009

NCI awards $11.5 million grant to UAB for cervical cancer research

The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center has won an $11.5 million grant from the National Cancer Institute (NCI) to explore groundbreaking cervical cancer research, prevention and treatment.

8 Oct 2009

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

5 Oct 2009

Merck, Qiagen pledge cervical cancer tools at CGI, meeting highlights effects of gender inequality

Drugmaker Merck & Co. announced Wednesday at the Clinton Global Initiative's (CGI) annual meeting in New York that it will "donate more than $500 million of its Gardasil cervical cancer vaccine" with the goal of improving women's health in developing countries, Bloomberg reports.

From QIAGEN Manchester Limited 28 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

New palate reconstruction technique for post tonsil cancer surgery

A new technique for reconstructing the palate after surgery for tonsil cancer maintained patients' ability to speak clearly and eat most foods, a new study shows.

23 Sep 2009

Chronic viruses found living in prostate tumors

According to Dr. Ila R. Singh, an associate professor of pathology at the University of Utah, "for the first time we have analyzed prostate cancer and normal prostate tissue and found cancers are much more likely to have [the XMRV virus] ... It was also more likely to be present in more aggressive tumors," Singh said. "We found it in 20 percent of the least aggressive tumors and over 45 percent of the most aggressive tumors."

21 Sep 2009

Merck, Wellcome Trust to launch vaccine center in India to produce vaccines for developing countries

Pharmaceutical company Merck and the Wellcome Trust have joined together to create a non-profit, £90-million (about $150 million) research center in India to facilitate the development of new vaccines, "including [those for] neglected diseases for which inadequate or no vaccines exist," Nature News reports.

18 Sep 2009

Inovio’s novel platform for developing DNA based vaccines to be discussed at EmTech

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, CEO, has been invited to present at EmTech, the Emerging Technologies Conference hosted by MIT and produced by MIT’s Technology Review magazine. The conference will take place September 22nd - 24th on the MIT campus in Cambridge, MA.

16 Sep 2009

New peptide-based cancer vaccine tested in genital cancer patients

Preventive vaccination against infectious diseases has been a major milestone for the health of modern society. The development of therapeutic vaccination against established diseases is much more difficult. For more than 100 years researchers have already tried to develop cancer vaccines and now first promising clinical results raise hopes. A summary of the most attractive new approaches gave Professor Carmen Scheibenbogen, Institut für Medizinische Immunologie, Charité-Universitätsmedizin, at a press conference in Berlin.

16 Sep 2009

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that clinical data support both the efficacy and safety of CERVARIX((R)), the company's candidate cervical cancer vaccine (12-1 and 11-1, respectively).

10 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

Chinese SFDA approves China Medical Technologies' SPR System

Majority of girls and young women well aware of HPV vaccine's benefits and limitations

Phase I clinical study of PENNVAX-B preventive DNA vaccine using electroporation technology

FDA approves Gardasil vaccine usage in boys and men for preventing genital warts

GlaxoSmithKline receives FDA approval for cervical cancer vaccine

Vaccination against HPV will help decrease cervical cancer death rate in India

Research study on HPV vaccination efficacy for boys and girls

New study finds rare type of head and neck cancer caused by HPV

NCI awards $11.5 million grant to UAB for cervical cancer research

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

Merck, Qiagen pledge cervical cancer tools at CGI, meeting highlights effects of gender inequality

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

New palate reconstruction technique for post tonsil cancer surgery

Chronic viruses found living in prostate tumors

Merck, Wellcome Trust to launch vaccine center in India to produce vaccines for developing countries

Inovio’s novel platform for developing DNA based vaccines to be discussed at EmTech

New peptide-based cancer vaccine tested in genital cancer patients

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

Merck's GARDASIL receives approval from FDA Advisory Committee

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in